A laminin-based therapy for dogs with chronic spinal cord injury: promising results of a longitudinal trial

IntroductionPolylaminin, an improved form of the natural protein laminin, has been shown to promote axonal regeneration and functional recovery in animal models of acute spinal cord injury (SCI), and is safe and potentially beneficial in humans when administered within the first days after traumatic...

Full description

Saved in:
Bibliographic Details
Main Authors: Carolina de Miranda Chize, Diego Gonzales Vivas, Karla Menezes, Max Nascimento Freire, Rodrigo Ferreira Pinto Jiddu, Aurélio Vicente Graça-Souza, Eliel de Souza-Leite, Paulo Roberto Louzada, Tatiana Coelho-Sampaio
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Veterinary Science
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fvets.2025.1592687/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849406957146865664
author Carolina de Miranda Chize
Carolina de Miranda Chize
Diego Gonzales Vivas
Karla Menezes
Max Nascimento Freire
Rodrigo Ferreira Pinto Jiddu
Aurélio Vicente Graça-Souza
Eliel de Souza-Leite
Paulo Roberto Louzada
Tatiana Coelho-Sampaio
author_facet Carolina de Miranda Chize
Carolina de Miranda Chize
Diego Gonzales Vivas
Karla Menezes
Max Nascimento Freire
Rodrigo Ferreira Pinto Jiddu
Aurélio Vicente Graça-Souza
Eliel de Souza-Leite
Paulo Roberto Louzada
Tatiana Coelho-Sampaio
author_sort Carolina de Miranda Chize
collection DOAJ
description IntroductionPolylaminin, an improved form of the natural protein laminin, has been shown to promote axonal regeneration and functional recovery in animal models of acute spinal cord injury (SCI), and is safe and potentially beneficial in humans when administered within the first days after traumatic SCI. This study aimed to evaluate the effect of polylaminin in dogs with chronic SCI.MethodsWe conducted a prospective, longitudinal study in six paraplegic dogs with severe chronic thoracolumbar SCI (T3-L3) caused by trauma (n = 2) or disc degeneration (n = 4). The study assessed whether gait scores, measured during an extended screening period (at least 4 months), would improve during the follow-up (6 months). Polylaminin was delivered intraspinally at a dose of 1 μg/kg, in combination with either glial-derived neurotrophic factor (GDNF; Group 1; n = 3) or chondroitinase ABC (Group 2; n = 3). Safety was assessed through neurological examinations, blood tests and monitoring of medical complications. Gait analysis was carried out using the Texas Spinal Cord Injury Scale (TSCIS) and the Open Field Scale (OFS), while a linear mixed model was used for statistical analysis. During the screening period, dogs received physiotherapy twice per week and had their gait scored periodically. The first six dogs whose scores had remained stable across three evaluations were enrolled. After owners provided informed consent, dogs were randomly allocated to either treatment group.ResultsNo neurological deterioration, serious clinical events or notable deviations in blood tests were observed. The TSCIS average baseline score increased from 2.2 to 3.2 (95% CI: 0.77–1.2; p < 0.001), while the OFS score increased from 1.5 to 3.1 (95% CI: 1.3–1.9; p < 0.001).DiscussionAlthough the present study could not discriminate between the benefits of the two treatments, our findings suggest that polylaminin, in combination with GDNF or chondroitinase ABC, is a safe and potentially effective treatment, which underscores the relevance of further studies to establish a new approach to improving gait function in dogs with chronic SCI.
format Article
id doaj-art-2cac1f073bb24fbc8f43a2956298d189
institution Kabale University
issn 2297-1769
language English
publishDate 2025-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Veterinary Science
spelling doaj-art-2cac1f073bb24fbc8f43a2956298d1892025-08-20T03:36:13ZengFrontiers Media S.A.Frontiers in Veterinary Science2297-17692025-08-011210.3389/fvets.2025.15926871592687A laminin-based therapy for dogs with chronic spinal cord injury: promising results of a longitudinal trialCarolina de Miranda Chize0Carolina de Miranda Chize1Diego Gonzales Vivas2Karla Menezes3Max Nascimento Freire4Rodrigo Ferreira Pinto Jiddu5Aurélio Vicente Graça-Souza6Eliel de Souza-Leite7Paulo Roberto Louzada8Tatiana Coelho-Sampaio9Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilPathology Program, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilUniversity Estacio de Sá, Rio de Janeiro, BrazilInstitute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilInstitute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilInstitute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilInstitute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilInstitute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilInstitute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilInstitute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilIntroductionPolylaminin, an improved form of the natural protein laminin, has been shown to promote axonal regeneration and functional recovery in animal models of acute spinal cord injury (SCI), and is safe and potentially beneficial in humans when administered within the first days after traumatic SCI. This study aimed to evaluate the effect of polylaminin in dogs with chronic SCI.MethodsWe conducted a prospective, longitudinal study in six paraplegic dogs with severe chronic thoracolumbar SCI (T3-L3) caused by trauma (n = 2) or disc degeneration (n = 4). The study assessed whether gait scores, measured during an extended screening period (at least 4 months), would improve during the follow-up (6 months). Polylaminin was delivered intraspinally at a dose of 1 μg/kg, in combination with either glial-derived neurotrophic factor (GDNF; Group 1; n = 3) or chondroitinase ABC (Group 2; n = 3). Safety was assessed through neurological examinations, blood tests and monitoring of medical complications. Gait analysis was carried out using the Texas Spinal Cord Injury Scale (TSCIS) and the Open Field Scale (OFS), while a linear mixed model was used for statistical analysis. During the screening period, dogs received physiotherapy twice per week and had their gait scored periodically. The first six dogs whose scores had remained stable across three evaluations were enrolled. After owners provided informed consent, dogs were randomly allocated to either treatment group.ResultsNo neurological deterioration, serious clinical events or notable deviations in blood tests were observed. The TSCIS average baseline score increased from 2.2 to 3.2 (95% CI: 0.77–1.2; p < 0.001), while the OFS score increased from 1.5 to 3.1 (95% CI: 1.3–1.9; p < 0.001).DiscussionAlthough the present study could not discriminate between the benefits of the two treatments, our findings suggest that polylaminin, in combination with GDNF or chondroitinase ABC, is a safe and potentially effective treatment, which underscores the relevance of further studies to establish a new approach to improving gait function in dogs with chronic SCI.https://www.frontiersin.org/articles/10.3389/fvets.2025.1592687/fullspinal cord injurychroniclamininpolylamininchondroitinase ABCGDNF
spellingShingle Carolina de Miranda Chize
Carolina de Miranda Chize
Diego Gonzales Vivas
Karla Menezes
Max Nascimento Freire
Rodrigo Ferreira Pinto Jiddu
Aurélio Vicente Graça-Souza
Eliel de Souza-Leite
Paulo Roberto Louzada
Tatiana Coelho-Sampaio
A laminin-based therapy for dogs with chronic spinal cord injury: promising results of a longitudinal trial
Frontiers in Veterinary Science
spinal cord injury
chronic
laminin
polylaminin
chondroitinase ABC
GDNF
title A laminin-based therapy for dogs with chronic spinal cord injury: promising results of a longitudinal trial
title_full A laminin-based therapy for dogs with chronic spinal cord injury: promising results of a longitudinal trial
title_fullStr A laminin-based therapy for dogs with chronic spinal cord injury: promising results of a longitudinal trial
title_full_unstemmed A laminin-based therapy for dogs with chronic spinal cord injury: promising results of a longitudinal trial
title_short A laminin-based therapy for dogs with chronic spinal cord injury: promising results of a longitudinal trial
title_sort laminin based therapy for dogs with chronic spinal cord injury promising results of a longitudinal trial
topic spinal cord injury
chronic
laminin
polylaminin
chondroitinase ABC
GDNF
url https://www.frontiersin.org/articles/10.3389/fvets.2025.1592687/full
work_keys_str_mv AT carolinademirandachize alamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT carolinademirandachize alamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT diegogonzalesvivas alamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT karlamenezes alamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT maxnascimentofreire alamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT rodrigoferreirapintojiddu alamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT aureliovicentegracasouza alamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT elieldesouzaleite alamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT paulorobertolouzada alamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT tatianacoelhosampaio alamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT carolinademirandachize lamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT carolinademirandachize lamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT diegogonzalesvivas lamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT karlamenezes lamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT maxnascimentofreire lamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT rodrigoferreirapintojiddu lamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT aureliovicentegracasouza lamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT elieldesouzaleite lamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT paulorobertolouzada lamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial
AT tatianacoelhosampaio lamininbasedtherapyfordogswithchronicspinalcordinjurypromisingresultsofalongitudinaltrial